DNTH Valuation
Dianthus Therapeutics Inc
$
19.110
- Overview
- Forecast
- Valuation
DNTH Relative Valuation
DNTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNTH is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for DNTH's competitors is 44.37, providing a benchmark for relative valuation. Dianthus Therapeutics Inc Corp (DNTH) exhibits a P/S ratio of 194.52, which is 338.45% above the industry average. Given its robust revenue growth of 33.07%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
ZJK
ZJK Industrial Co Ltd
4.810
USD
+6.89%
ACIC
American Coastal Insurance Corp
11.180
USD
+4.29%
KODK
Eastman Kodak Co
6.450
USD
-1.53%
AUTL
Autolus Therapeutics PLC
1.530
USD
+3.38%
GRAL
Grail Inc
39.320
USD
+2.85%
UPB
Upstream Bio Inc
9.130
USD
+0.88%
LDI
Loandepot Inc
1.290
USD
+4.88%
IRWD
Ironwood Pharmaceuticals Inc
0.652
USD
+6.54%
FARO
FARO Technologies Inc
42.110
USD
+0.02%
CMP
Compass Minerals International Inc
19.660
USD
+2.13%
FAQ
Is Dianthus Therapeutics Inc (DNTH) currently overvalued or undervalued?
Dianthus Therapeutics Inc (DNTH) is now in the Fair zone, suggesting that its current forward PS ratio of 194.52 is considered Fairly compared with the five-year average of 268.61. The fair price of Dianthus Therapeutics Inc (DNTH) is between 9.57 to 34.98 according to relative valuation methord.
What is Dianthus Therapeutics Inc (DNTH) fair value?
How does DNTH's valuation metrics compare to the industry average?
What is the current P/B ratio for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?
What is the current FCF Yield for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?
What is the current Forward P/E ratio for Dianthus Therapeutics Inc (DNTH) as of May 20 2025?